急性心肌梗死药物治疗研究进展被引量：27

Advances in Drug Therapy for Acute Myocardial Infarction

下载PDF

导出

摘要急性心肌梗死的治疗主要涉及药物和介入两个方面。及时有效的介入治疗能迅速开通阻塞的冠状动脉、挽救濒死心肌,降低急性心肌梗死病人的病死率和病残率。与介入治疗相比,强化的药物治疗方案不仅价格便宜,而且更容易推广实施。现就有关的药物治疗现状及进展作一综述。 Acute myocardial infarction therapy involves two primary areas—pharmaceuticals and intervention.Intervention can quickly open the occlusive coronary artery,save the endangered myocardium and reduce the mortality of patients with acute myocardial infarction.When compared with interventional therapy,drug treatment was not only cheaper,but also easier in its application.This review examines advances in medications used in acute myocardial infarction.

作者张力俨张翠丽富路

机构地区哈尔滨医科大学附属第一医院心内科

出处《心血管病学进展》 CAS 2011年第2期212-216,共5页 Advances in Cardiovascular Diseases

关键词急性心肌梗死治疗病死率 acute myocardial infarction therapy mortality

分类号 R542.22 [医药卫生—心血管疾病]

引文网络
相关文献

参考文献25

1Orso F, Maggioni AP. What is the optimal reperfusion strategy for elderly pa- tients with acute MI[J] ? Am J Geriatr Cardiol, 2006, 15:14-18.
2Cleland JG, Caletta AP, Freemantle N, et al. Clinical trials update from the A- merican College of Cardiology meeting: CARE-HF and the remission of heart failure, Women's Health Study, TNT, COMPASS-HF, VERITAS, CANPAP, PEECH and PREMIER[J]. Eur J Heart Fail, 2005, 7:931-936.
3Moser M, Bode C. Pharmacology and clinical trial results of saruplase (scuPA) in acute myocardial infarction [ J ]. Expert Opin Investig Drugs, 1999, 8 : 329- 335.
4Moser M, Kohler B, Schmitmer M, et al. Recombinant plasminogen activators:a comparative review of the clinical pharmacology and therapeutic use of alteplase and reteplase[J]. BioDrugs, 1998, 9:455-463.
5Stepitska J, Sadowski Z, Szajewski T, et al. Calcium blocker therapy before myocardial infarction increases post-infarction short-and long-term mortality. Da- ta from the INJECT trial[J]. Kardiol Pal, 2002, 57:512-519.
6VanI Hof AW, Ten Berg J, Heestermans T, et al. Prehospital initiation of tirofiban in patients with ST-elevation myocardial infarction undergoing primary angioplasty ( On-TIME 2 ) : a muhicentre, double-blind, randomised controlled trial[J]. Lancet, 2008, 372: 537-546.
7Widimsky P, Bilkova D, Penicka M, et all. Long-term outcomes of patients with acute myocardial infarction presenting to hospitals without catheterization laboratory and randomized to immediate thrombolysis or interhospital transport for primary percutaneous coronary intervention. Five years'follow-up of the PRAGUE- 2 Trial[J]. Eur Heart .J. 2007,28:670-684.
8Hermlann HC, Lu J, Brodie BR, et al. Benefit of facilitated percutaneous coro- nary intervention in high-risk ST-segment elevation myocardial infarction patients presenting to nonpereutaneous coronary intervention hospitals[J]. JACC Cardiovasc Interv , 2009, 2:917-924.
9Johanson P, Fu Y, Wagner GS, et al. ST resolution 1 hour after fibrinolysis for prediction of myocardial infarct size: insights from ASSENT 3 [ J ]. Am J Cardiol, 2009, 103 : 154-158.
10French JK, Edmond JJ, Gao W, et al. Adjunctive use of direct thrombin inhibitors in patients receiving fibrinolytic therapy for acute myocardial infarction [ J ]. Am J Cardiovasc Drugs, 2004, 4:107-115.